Early initiation of the sodium glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin did not result in a statistically significant improvement in diuretic efficiency relative to structured usual ...
Madrid, Spain – 30 August 2025: In-hospital initiation of dapagliflozin did not significantly reduce the short-term risk of cardiovascular death or worsening heart failure (HF) in patients admitted ...
Rates of inpatient dialysis initiation are higher for patients with chronic kidney disease and heart failure than those without heart failure. HealthDay News — Patients with chronic kidney disease ...
MINNEAPOLIS, Jan. 22, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (CVRX) (NASDAQ: CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions ...
Findings showed that patients treated with empagliflozin were 36% more likely to experience a clinical benefit. Treatment with empagliflozin was shown to improve clinical outcomes in adults ...
Heart attacks and strokes remain the leading cause of complications and mortality for patients with diabetes. Statin therapy reduces the risk of these cardiovascular events by preventing plaque ...
Evidence continues to support initiation of sodium glucose cotransporter 2 inhibitors in patients with heart failure. The initial decline in estimated glomerular filtration rate (eGFR) after starting ...
SOUTH SAN FRANCISCO, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: CYTK) today announced nine presentations at the European Society of Cardiology Heart Failure 2026 Congress taking place in ...
More frequent placement of central venous catheter seen for patients with heart failure with reduced ejection fraction. (HealthDay News) — Patients with chronic kidney disease (CKD) and heart failure ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results